Genetic Factors and Weight Loss After Bariatric Surgery
Studies whether genes predict weight loss in adults with severe obesity after surgery.
Plain-language title generated from the registry record
Registry title: Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery
Key facts
- Where
- Lleida, SpainSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06226194, who can take part
Where in Spain
- IRBLleidaLleida, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut de Recerca Biomèdica de Lleida
- Trial code
- NCT06226194
- Record updated
- 6 March 2024
- Original description
Obesity is a complex chronic disease, in which both genetic and environmental factors are involved, that shows a great heterogeneity in the response to different weight loss programs. Identifying patients as responder or no responder to the different obesity treatment options is a concept of great interest, both due to the high prevalence of obesity and its high consumption of resources. More than 500,000 surgeries are performed every year around the world, of which approximately 30% will present unsatisfactory results.Read full original descriptionShow less
Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery
Obesity is a complex chronic disease, in which both genetic and environmental factors are involved, that shows a great heterogeneity in the response to different weight loss programs. Identifying patients as responder or no responder to the different obesity treatment options is a concept of great interest, both due to the high prevalence of obesity and its high consumption of resources. More than 500,000 surgeries are performed every year around the world, of which approximately 30% will present unsatisfactory results.
The general objective is to carry out a multi-omics approach for the discovery and validation of markers of weight response to bariatric surgery (BS) in a large sample of people with severe obesity (n=6,966 men and women who underwent sleeve gastrectomy or gastric bypass, including an additional external validation set). Thus, the investigators want to know the integrated contribution of several genomic markers (Genome Wide Association study, GWAs), new clinical and analytical variables (human exposome concept) and gender perspective to the prediction of response to the intervention at 12 month and its long-term longitudinal maintenance (3 years). The investigators intend, therefore, to provide new evidence to advance towards precision medicine. The investigators will focus our attention also on identifying those patients who, after being classified at the weight loss nadir as responders experienced weight regain.
Inclusion: Men and women between the ages of 18 and 65 at the time of surgery; SG or RYBP as bariatric procedure; With a BMI≥35.0 kg/m2 with one or more comorbidities or a BMI>40.0 kg/m2 at the time of surgery; Provision of an informed consent form signed and personally dated by the patient; With available baseline data (anthropometric, analytical, surgical procedure, pharmacological therapies, and obesity-related comorbidities).
Exclusion: Any previous gastrointestinal surgery; Treatment with any approved antiobesity drug in Spain (orlistat, liraglutide 3.0 mg and/or naltrexone/bupropion extended release) or systemic glucocorticoids for more than 4 consecutive weeks during the 3 years following BS; Current drug or alcohol abuse; Patients who developed any major medical conditions that limits the practice of a healthy life within normal limits (advanced cardiovascular disease or heart failure, stroke with neurological sequelae, chronic pulmonary obstructive disease with dyspnea at minimal exertion, severe joint pathology, end stage renal failure, or active cancer); Known type 1 diabetes or LADA diabetes; Uncontrolled psychiatric illness or eating disorders developed during the follow-up period; End stage kidney disease (eGFR <15 ml/min/1.73m2) or liver cirrhosis at baseline; Women who become pregnant during the follow-up period.